Neurofibromatosis type 1 (NF1) is an autosomal dominant human
genetic disorder. The progression of benign
plexiform neurofibromas to malignant peripheral nerve sheet
tumors (MPNSTs) is a major cause of mortality in patients with NF1. Although elevated
epidermal growth factor receptor (EGFR) expression plays a crucial role in the pathogenesis of
MPNST, the cause of EGFR overexpression remains unclear. Here, we assessed EGFR expression levels in
MPNST tissues of NF1 patients and NF1 patient-derived
MPNST cells. We found that the expression of EGFR was upregulated in
MPNST tissues and
MPNST cells, while the expression of
neurofibromin was significantly decreased. Manipulation of NF1 expression by NF1
siRNA treatment or NF1-GAP-related domain overexpression demonstrated that EGFR expression levels were closely and inversely correlated with
neurofibromin levels. Notably, knockdown of the NF1 gene by
siRNA treatment augmented the nuclear localization of phosphorylated SP1 (pSP1) and enhanced pSP1 binding to the EGFR gene promoter region. Our results suggest that
neurofibromin deficiency in NF1-associated MPNSTs enhances the Ras/ERK/SP1 signaling pathway, which in turn may lead to the upregulation of EGFR expression. This study provides insight into the progression of benign
tumors and novel therapeutic approaches for treatment of NF1-associated MPNSTs.